Copyright
©The Author(s) 2003.
World J Gastroenterol. Jun 15, 2003; 9(6): 1208-1211
Published online Jun 15, 2003. doi: 10.3748/wjg.v9.i6.1208
Published online Jun 15, 2003. doi: 10.3748/wjg.v9.i6.1208
Parameters | TAE group(n = 102) | Control group(n = 185) | P |
Male (%) | 75 (74.3%) | 148 (80%) | NS |
Age (years)* | 56.7 ± 10.5 | 56.8 ± 13.7 | NS |
Albumin (g/dl)* | 3.51 ± 0.57 | 3.40 ± 0.61 | NS |
Bilirubin (mg/dl)* | 2.02 ± 7.17 | 1.30 ± 1.25 | NS |
ALT (IU/ml)* | 68.4 ± 63.6 | 63.0 ± 57.1 | NS |
Prolonged Prothrombin time* | 1.38 ± 1.25 | 1.48 ± 1.11 | NS |
Encephalopathy (%) | 6 (5.9%) | 14 (7.6%) | NS |
Cirrhosis (%) | 76 (74.5%) | 121 (65.4%) | NS |
Ascites (%) | 14 (13.7%) | 32 (17.3%) | NS |
Multicentric tumors (%) | 19 (18.6%) | 39 (21.1%) | NS |
Heterogeneous echopattern (%) | 34 (33.4%) | 72 (39.1%) | NS |
Encapsulated tumors (%) | 49 (48.0%) | 76 41.1%) | NS |
PV thrombosis (%) | 23 (22.5%) | 58 (31.4%) | NS |
Large tumor size (%) | 56 (54.9%) | 103 (55.7%) | NS |
- Citation: Lin SC, Shih SC, Kao CR, Chou SY. Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis. World J Gastroenterol 2003; 9(6): 1208-1211
- URL: https://www.wjgnet.com/1007-9327/full/v9/i6/1208.htm
- DOI: https://dx.doi.org/10.3748/wjg.v9.i6.1208